Phase 3 Clinical Trials
Pivotal, large-scale trials that confirm a drug’s efficacy and safety. Positive Phase 3 data is usually the gateway to FDA submission.
August 202610
September 202623
Gentamicin, Cefazolin and Vancomycin Phase 3 Est. Readout
October 202630
[O-15]-Water PET Myocardial Perfusion Imaging (MPI) Phase 3 Est. Readout
November 202627
Mometasone furoate nasal spray (MFNS) Phase 3 Est. Readout
Cretostimogene Grenadenorepvec Phase 3 Est. Readout
December 202610
Bacillus Calmette-Guerin Vaccine Intravesical Phase 3 Est. Readout
About Phase 3 Clinical Trials
Phase 3 clinical trials are large, randomized, often placebo- or active-controlled studies that test a drug’s efficacy and safety in hundreds to thousands of patients. They are the pivotal trials regulators rely on to decide whether a therapy works well enough to approve.
A Phase 3 program typically reads out on pre-specified primary and secondary endpoints. Topline results — the first public disclosure of whether the trial hit its main endpoint — are the market-moving moment, well before the full data appears at a medical congress or in a peer-reviewed journal.
Why Phase 3 Trials matter to investors
Phase 3 readouts are high-variance catalysts: a hit clears the path to an NDA/BLA and often a partnership or run-up, while a miss can erase most of a clinical-stage company’s value in a single session. Historically around 58% of drugs that reach Phase 3 ultimately win approval — better than a coin flip, but far from certain — so the readout is where much of a pipeline’s risk is priced.
Frequently asked questions
What is a Phase 3 clinical trial?
A Phase 3 trial is a large, pivotal study — often hundreds to thousands of patients — that confirms a drug’s efficacy and safety and forms the basis of an FDA or EMA submission.
What does a Phase 3 “topline” readout mean?
Topline results are the first public disclosure of whether the trial met its primary endpoint. They arrive before the full dataset and are the main price-moving event.
How often do Phase 3 trials succeed?
Success is far from guaranteed — historically around 58% of drugs that reach Phase 3 go on to approval, which is why a positive readout can re-rate a stock and a failure can be severe.